Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the most common questions he has been asked regarding the ENCORE study, which are: what are the characteristics of the patients that went into the study, how long has it been since the patients progressed, and are these patients who initially had a response and then progress? This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Questions Regarding ENCORE Study
